Shubham Pant, MD, Highlights Outcomes With Erdafitinib in Gastrointestinal Cancers

Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal and other solid tumor malignancies.

In an interview with CancerNetwork®, Shubham Pant, MD, associate professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlighted key findings from a basket trial presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting that examined the use of erdafitinib (Balversa) in gastrointestinal (GI) cancers.


One is a basket trial for patients with FGFR alterations, [including] driver mutations or fusions, with [treatment with] a drug called erdafitinib, which is an FGFR inhibitor. We presented the data at this ASCO in which we did a basket trial in non-bladder cancers, [including] a lot of GI cancers, glioblastoma, and other cancers. What we saw was that there was an overall response rate in this unselected tumor agnostic population of about 30%. What was even more exciting was that our patients with cholangiocarcinoma had response rates of up to 50% and patients with pancreatic cancer—a very hard to treat malignancies [with] outcomes that are not that great—had response rates of 30%. We were very excited about presenting the data at ASCO.


Loriot Y, Schuler MH, Iyer G, et al. Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results. J Clin Oncol. 2022;40(suppl 16):3007. doi: 10.1200/JCO.2022.40.16_suppl.3007

Related Videos
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
Related Content